Accustem Sciences Inc. (ACUT)
OTCMKTS: ACUT · Delayed Price · USD
0.276
0.00 (0.00%)
Apr 23, 2024, 9:30 AM EDT - Market open
Company Description
AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing products for the treatment and management of various cancers.
Its primary product candidate is StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients.
The company was founded in 2013 and is headquartered in New York, New York.
Accustem Sciences Inc.
| Country | NY |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Ms. Wendy E. Blosser |
Contact Details
Address: 5 Penn Plaza, 19th Floor, #1954 New York, New York 10001 United States | |
| Phone | 442070661000 |
| Website | accustem.com |
Stock Details
| Ticker Symbol | ACUT |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001850767 |
| CUSIP Number | 00444A101 |
| ISIN Number | US00444A1016 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gabriele Marco Antonio Cerrone M.B.A. | Executive Chairman of the Board |
| Wendy E. Blosser | Chief Executive Officer and Director |
| Joe Flanagan | Chief Business Officer |
| Keeren Shah | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 10, 2024 | 8-K | Current Report |
| Mar 22, 2024 | 10-K | Annual Report |
| Nov 13, 2023 | 10-Q | Quarterly Report |
| Aug 14, 2023 | 10-Q | Quarterly Report |
| Jun 9, 2023 | 8-K | Current Report |
| Jun 7, 2023 | 8-K | Current Report |
| May 5, 2023 | 10-Q | Quarterly Report |
| Apr 28, 2023 | 10-K/A | [Amend] Annual report |
| Feb 15, 2023 | 10-K | Annual Report |
| Jan 19, 2023 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |